Dillico

What Dillico does

Dillico is a French deeptech company developing the All-ScaleFlow™ platform, the world's first All-Scale-in-One continuous manufacturing solution for mRNA-LNP products spanning from In-Vitro Transcription (IVT) to LNP encapsulation in a single integrated system. The technology uses a proprietary continuous meso-fluidic process that enables scale-up-free production from 1,000 doses to 30-300 million doses per year using identical equipment, replacing traditional batch skid trains that typically span hundreds of square meters with a 5 sq/m automated footprint. The system is complemented by the mRNAfacturing™ digital infrastructure — providing process modeling, PATs, real-time monitoring, and remote control — and an Evidence Package service for customer demonstrations and at-scale pilot runs.

The company generates revenue (or intends to) through three streams: equipment sales of the All-ScaleFlow™ system, professional services via the Evidence Package, and managed digital services through mRNAfacturing™. Its go-to-market is enterprise field sales targeting biopharma and vaccine manufacturers globally, with a parallel distribution focus on regional and low-/middle-income country production via partnerships such as the CRADA with WHO-designated Afrigen Biologics. Founded in May 2022 by Christophe Bonneville (CEO, ex-Resolution Spectra/Merck Millipore), Flora Binder (CDO, ex-Moderna/Biogen), and Emmanuel Gaud (COO, 23 years life-sciences process engineering), Dillico is headquartered in Meylan near Grenoble, employs approximately 11 people, and remains a private company with no disclosed revenue as of mid-2025.

Name

Dillico

Legal name

DILLICO SAS

Website

https://dillico.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

1–10 employees

Short description

Dillico is a French deeptech company developing All-ScaleFlow™, an integrated continuous manufacturing platform that enables scale-up-free mRNA-LNP vaccine and therapy production from 1,000 to 300 million doses annually on a 5 sq/m footprint, serving global biopharma companies and regional manufacturers including WHO-partnered LMIC hubs.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Manufacturing Equipment

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Misc Industrial & Commercial Machinery & Equipment (3590), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Plasmid DNA & mRNA Manufacturing Services (HLAAAKAE)

akta.pro secondary industry

GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL)

Keywords

• MRNA manufacturing equipment
• Continuous bioprocessing
• LNP encapsulation systems
• Vaccine production technology
• Biopharmaceutical automation

Headquarters

HQ city

Meylan

HQ country

France

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Equipment Sales: Sale of All-ScaleFlow™ automated manufacturing equipment for mRNA-LNP production to biopharma companies, vaccine manufacturers, and regional production facilities
2. Evidence Package & Process Development Services: Evidence Package providing demonstrations with user-specified sequences and raw materials, including process compatibility testing, performance validation, and at-scale pilot runs
3. mRNAfacturing™ Services: Digital tools and services infrastructure to help customers overcome challenges in mRNA-LNP production from early-development to commercial production, including technology transfer support

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

Dillico designs, manufactures and sells the All-ScaleFlow™ automated equipment system for end-to-end mRNA-LNP production, from In-Vitro Transcription through purification to LNP encapsulation. The same equipment supports production from 1,000 doses in a few hours to 30-300 million doses per year, replacing traditional batch skid trains with a single integrated 5 sq/m unit. Dillico also provides the mRNAfacturing™ digital infrastructure (real-time monitoring, PAT, process modeling, remote control) and the Evidence Package service for customer validation, technology transfer support, and at-scale pilot runs.

Product overview

Dillico offers a unified platform-plus-modules product architecture centered on the All-ScaleFlow™ system—the world's first All-Scale-in-One mRNA manufacturing solution that enables end-to-end production of mRNA-LNP from In-Vitro Transcription to LNP encapsulation at any scale using the same equipment. The core All-ScaleFlow™ system is complemented by mRNAfacturing™ (digital infrastructure providing real-time monitoring, process modeling, and PAT integration) and an Evidence Package (customer onboarding service offering demonstrations, validation testing, and economic analysis). This integrated approach combines hardware manufacturing with software/digital services to deliver a complete solution from pre-clinical development through commercial-scale production.

Differentiator

Problem solved

Functional benefit

Brands

• All-ScaleFlow™: The world's first All-Scale-in-One mRNA manufacturing solution enabling end-to-end production of mRNA-LNP from In-Vitro Transcription to LNP encapsulation at any scale using the same equipment.
• mRNAfacturing™

Products and services

• All-ScaleFlow™ World's first All-Scale-in-One mRNA manufacturing solution that enables end-to-end production of mRNA-LNP from In-Vitro Transcription to LNP encapsulation at any scale using the same equipment and process design space. Supports production from 1,000 doses in a few hours to 30-300 million doses per year within a 5 sq/m automated equipment footprint, with GMP-compliant design, integrated PAT, and raw-material agnostic process. Sold to biopharmaceutical companies, vaccine manufacturers, and regional production facilities.
• mRNAfacturing™ Infrastructure of digital tools and services tailored to help customers overcome challenges in mRNA-LNP production from early development to commercial manufacturing. Includes real-time and remote monitoring, unified data flow, process modeling and simulator, and Process Analytical Technologies (PAT) for in-process control. Sold as a digital layer for All-ScaleFlow™ customers.
• Evidence Package Customer demonstration and validation service providing structured evaluations across RNA sequence process parameters, IVT/purification/LNP formulation processes, and customer-preferred raw materials. Includes Critical Quality Attributes (CQA) analysis by orthogonal methods and representative at-scale pilot runs with batch data package and economic study outputs, supporting technology transfer and informed purchasing decisions for biopharma customers.

Quantifiable outcome

• Annual production capacity of 30-300 million doses mRNA
• +3 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Two partnerships are on record, tiered core and supporting.

• Afrigen BiologicscoreStrategic or Co-development Partner · 25 May 2023Cooperative R&D Agreement (CRADA) to test scalability and effectiveness of Dillico's continuous mRNA-LNP manufacturing solution adapted for low- and middle-income countries. Afrigen Biologics is the global mRNA technology development and transfer hub appointed by WHO in June 2021. Prof Petro Terblanche, CEO of Afrigen, stated excitement about testing Dillico's innovative technology for addressing unmet healthcare needs in Africa.
• LyonbiopôlesupportingOthersListed as partner/logo on website. Lyonbiopôle is a biotech/health cluster in Auvergne-Rhône-Alpes region supporting innovative companies in the sector.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Cytiva: Cytiva (Danaher) is a global bioprocessing equipment and services leader serving mRNA manufacturers with batch and continuous manufacturing solutions. As the dominant incumbent in the bioprocessing equipment market that Dillico is targeting, Cytiva represents the primary competitive incumbent Dillico must displace or differentiate against.
• Thermo Fisher Scientific: Thermo Fisher operates Patheon CDMO services alongside its bioprocessing equipment portfolio, serving mRNA developers with both manufacturing capacity and process technology. Comparable because it is a major incumbent selling both manufacturing equipment and services to the same biopharma customers Dillico targets.
• Merck MilliporeSigma: Merck's Life Science division provides bioprocessing equipment, raw materials, and CDMO services for mRNA production, and notably acquired CEO Bonneville's prior company (Resolution Spectra) in 2020. It is the most directly comparable incumbent given its leadership position in mRNA manufacturing inputs and process monitoring.
• Lonza: Lonza is one of the largest CDMOs globally with established mRNA manufacturing capacity. Comparable because it provides both contract manufacturing services and process technology for mRNA developers, directly overlapping Dillico's biopharma customer base.

Direct peers

• Quantoom Biosciences: Quantoom Biosciences (a Univercells subsidiary) develops continuous mRNA manufacturing platforms including Ntensify and Nprouve platforms targeting accessible mRNA production. Most direct technical peer to Dillico, competing head-to-head on the thesis that continuous, miniaturized mRNA manufacturing will democratize the market.
• Univercells: Univercells pioneers continuous bioprocessing and vaccine manufacturing technologies with the mission of making biologics affordable and accessible globally. Closely aligned with Dillico's mission and technology approach (continuous, compact, scalable manufacturing) for vaccines including mRNA.
• TriLink BioTechnologies (Maravai): TriLink BioTechnologies (owned by Maravai LifeSciences) provides mRNA manufacturing services including CDNA, mRNA synthesis, and LNP formulation for clinical and commercial applications. Comparable because it operates as an mRNA manufacturing services provider to biopharma customers.
• Aldevron (Danaher): Aldevron (acquired by Danaher in 2021) provides plasmid DNA, mRNA, and protein manufacturing services to biopharma developers. Comparable as an mRNA manufacturing services provider targeting the same therapeutic development customer base as Dillico.
• Resilience: Resilience is a technology-focused biomanufacturing company building end-to-end capabilities across modalities including mRNA. Comparable because it combines manufacturing services with proprietary process technology to modernize biopharma production.

Others

• Afrigen Biologics: Afrigen Biologics is the WHO-appointed mRNA technology transfer hub and is Dillico's named strategic partner (CRADA). While not a direct equipment competitor, Afrigen is highly relevant because its adoption and endorsement of Dillico's platform in LMIC markets is a critical distribution channel and credibility signal for the company.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds2 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Dillico